person · Reporting owner

Monia Brett P

Disclosed activity across 2 companies

Tapewire entity: 1185
SEC CIK: 0001537529

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director · Chief Executive Officer	August 31, 2026	September 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

IONIS PHARMACEUTICALS INC

Report date August 31, 2026 · Filed September 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	242,760	Reported balance After 2026-08-31 transaction · row 1 1 source row Row 1 · 2026-08-31 · Other · Acquired 98 · Balance 242,760 F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2026. These shares may not be sold until February 28, 2027.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2017 Filed Jan 4, 2017 23:34 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantEmployee Stock Option (right to buy) · Derivative	48,000	$0.00 Strike: $47.34	$0.00	Disclosure SEC source: 0000874015-17-000006 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2024-01-02 F3 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 12,000 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document
January 03, 2017 Filed Jan 4, 2017 23:34 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	309	$48.60	$15,017.40	Disclosure SEC source: 0000874015-17-000006 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,872 F2 · kind: Acquired as a result of shares owned under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2016. The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. F2 · shares: Acquired as a result of shares owned under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2016. The sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 7/1/2014. Read SEC document
January 01, 2017 Filed Jan 4, 2017 23:34 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	OtherCommon Stock	309	$20.76	$6,413.91	Disclosure SEC source: 0000874015-17-000006 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,181 F1 · kind: Reporting 309 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 309 shares may not be sold until July 2, 2017. F1 · shares: Reporting 309 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These 309 shares may not be sold until July 2, 2017. Read SEC document
December 20, 2016 Filed Dec 20, 2016 23:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	SaleCommon Stock	130	$52.48	$6,822.40	Disclosure SEC source: 0000874015-16-000152 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · SVP, Antisense Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,872 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/1/2014. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/1/2014. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.